Linked Life Data

19435910

Source:http://linkedlifedata.com/resource/pubmed/id/19435910

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2009-5-18
pubmed:abstractText
Whereas transcriptional silencing of genes due to epigenetic mechanisms is one of the most important alterations in acute lymphoblastic leukemia (ALL), some recent studies indicate that DNA methylation contributes to down-regulation of miRNAs during tumorigenesis. To explore the epigenetic alterations of miRNAs in ALL, we analyzed the methylation and chromatin status of the miR-124a loci in ALL. Expression of miR-124a was down-regulated in ALL by hypermethylation of the promoter and histone modifications including decreased levels of 3mk4H3 and AcH3 and increased levels of 2mK9H3, 3mK9H3, and 3mK27H3. Epigenetic down-regulation of miR-124a induced an up-regulation of its target, CDK6, and phosphorylation of retinoblastoma (Rb) and contributed to the abnormal proliferation of ALL cells both in vitro and in vivo. Cyclin-dependent kinase 6 (CDK6) inhibition by sodium butyrate or PD-0332991 decreased ALL cell growth in vitro, whereas overexpression of pre-miR124a led to decreased tumorigenicity in a xenogeneic in vivo Rag2(-/-)gammac(-/-) mouse model. The clinical implications of these findings were analyzed in a group of 353 patients diagnosed with ALL. Methylation of hsa-miR-124a was observed in 59% of the patients, which correlated with down-regulation of miR-124a (P < 0.001). Furthermore, hypermethylation of hsa-miR-124a was associated with higher relapse rate (P = 0.001) and mortality rate (P < 0.001), being an independent prognostic factor for disease-free survival (P < 0.001) and overall survival (P = 0.005) in the multivariate analysis. These results provide the grounds for new therapeutic strategies in ALL either targeting the epigenetic regulation of microRNAs and/or directly targeting the CDK6-Rb pathway.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1538-7445
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
69
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4443-53
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:19435910-Animals, pubmed-meshheading:19435910-Cell Division, pubmed-meshheading:19435910-Cell Line, Tumor, pubmed-meshheading:19435910-Chromatin, pubmed-meshheading:19435910-Cyclin-Dependent Kinase 6, pubmed-meshheading:19435910-DNA-Binding Proteins, pubmed-meshheading:19435910-Disease Models, Animal, pubmed-meshheading:19435910-Disease-Free Survival, pubmed-meshheading:19435910-Down-Regulation, pubmed-meshheading:19435910-Epigenesis, Genetic, pubmed-meshheading:19435910-Female, pubmed-meshheading:19435910-Gene Silencing, pubmed-meshheading:19435910-Humans, pubmed-meshheading:19435910-Male, pubmed-meshheading:19435910-Mice, pubmed-meshheading:19435910-Mice, Knockout, pubmed-meshheading:19435910-MicroRNAs, pubmed-meshheading:19435910-Precursor Cell Lymphoblastic Leukemia-Lymphoma, pubmed-meshheading:19435910-Prognosis, pubmed-meshheading:19435910-RNA, Messenger, pubmed-meshheading:19435910-Survival Rate, pubmed-meshheading:19435910-Transcription, Genetic
pubmed:year
2009
pubmed:articleTitle
Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia.
pubmed:affiliation
Hematology Department and Area of Cell Therapy, Clinica Universitaria and Division of Gene Therapy and Hepatology, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't